In the 2020 National Science and Technology Awards, many stem cell research achievements are on the list!

On November 3, at the 2020 National Science and Technology Awards Conference held in Beijing, a number of research achievements in the field of cells won awards:

2020 National Natural Science Award (Second Prize)

2020 National Science and Technology Progress Award (Second Prize)

Among them, the First Affiliated Hospital of Soochow University, Fuwai Hospital of the Chinese Academy of Medical Sciences, Shanghai Institutes of Life Sciences of the Chinese Academy of Sciences, the First Hospital of Hebei Medical University, and the Institute of Biophysics of the Chinese Academy of Sciences jointly completed the project. Professor Shen Zhenya, Director of the Cardiac and Vascular Surgery Department of the First Affiliated Hospital of Soochow University, served as the first project completion person. 700; font-stretch: inherit; font-size: inherit; line-height: inherit; font-family: inherit; vertical-align: baseline;”>”Key technology innovation and clinical transformation of cell therapy for ischemic heart disease” is closely related to clinical practice.

The incidence of ischemic heart disease such as coronary heart disease and myocardial infarction is increasing year by year. Commonly used clinical drug treatments, interventional stents, surgical bypass and other methods can only improve myocardial blood supply, but cannot solve the problem of end-stage heart failure caused by myocardial cell loss caused by ischemia and secondary ventricular remodeling. The “Key Technology Innovation and Clinical Transformation of Cell Therapy for Ischemic Heart Disease” project jointly completed by the First Affiliated Hospital of Suzhou University and other units solved the above problems through cell therapy and won the second prize of the National Science and Technology Progress Award.

“We have established new theories and new methods for cell therapy of ischemic heart disease, and innovative key transplantation technologies have broken through the bottleneck of cell therapy for ischemic heart disease.” said Professor Shen Zhenya, Director of the Cardiac and Vascular Surgery Department of the First Affiliated Hospital of Suzhou University. The project has been promoted and applied in many hospitals in China, and has completed the clinical translation and application of cell therapy for ischemic heart disease with the largest sample size in China, bringing good news to patients.

In 2003, this stem cell transplantation technology was the first in China to be successfully used clinically. baseline;”>A total of 135 cases of stem cell transplantation (as of 2017) have been completed, and 83.3% of patients’ symptoms have been significantly improved.
—— Extended reading ——

On January 10, 2020, at the 2019 National Science and Technology Awards Conference held by the Central Committee of the Communist Party of China and the State Council in Beijing, the “Key Technology Innovation and Clinical Application Research of Allogeneic Mesenchymal Stem Cells in the Treatment of Refractory Lupus Erythematosus” jointly completed by Sun Lingyun from the Department of Rheumatology and Immunology of Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Hu Junyuan (formerly known as Hu Xiang) of Shenzhen Beike Biotechnology Co., Ltd. won the award National Technology Invention Award.